COMMUNIQUÉS West-GlobeNewswire
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
28/01/2026 -
Women’s Health Collective Canada Announces Vital Talks Event on Menstruation and Lifelong Hormonal Health, Presented by Vichy Laboratoires
28/01/2026 -
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
28/01/2026 -
Park Dental Partners Expands Presence in Arizona with Addition of Ironwood Dental
28/01/2026 -
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026 -
Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma
28/01/2026 -
Future Communities Institute, with Akido Labs, Five Keys, and ReImagine Freedom Launch the Bay Area’s First AI-Powered Safety Net Program
28/01/2026 -
MEDVI Quad Prescription Information Updated as Consumer Interest in Prescription Erectile Dysfunction Treatment Access Through Telehealth Platforms Grows in 2026
28/01/2026 -
GUERBET : Karim Boussebaa nommé Directeur général
28/01/2026 -
Guerbet: Karim Boussebaa appointed Chief Executive Officer
28/01/2026 -
Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments
28/01/2026 -
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
28/01/2026 -
NADP Foundation Announces 2026 Grants
28/01/2026 -
Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
28/01/2026 -
Altanine Appoints Patrice Launay as Chief Financial Officer
28/01/2026 -
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
28/01/2026 -
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
28/01/2026 -
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026 -
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
28/01/2026
Pages